Yoshitake Murayama
Saitama, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Therapy-related acute promyelocytic leukemia developing during chemotherapy for thymic carcinoma
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: September 10, 2020
Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50.
Journal: Scientific reports
Published: March 23, 2020
Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer.
Journal: Journal of clinical medicine
Published: February 15, 2020
Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events.
Journal: Thoracic cancer
Published: January 24, 2020
Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation.
Journal: Thoracic cancer
Published: December 08, 2019
Correction to: Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
Journal: Cancer chemotherapy and pharmacology
Published: November 10, 2019
CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy.
Journal: Cancer immunology research
Published: July 27, 2019
Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer.
Journal: Cancer chemotherapy and pharmacology
Published: July 21, 2019
Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer.
Journal: Thoracic cancer
Published: January 28, 2019
Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab.
Journal: Thoracic cancer
Published: January 24, 2019
Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients.
Journal: Thoracic cancer
Published: January 06, 2019
Last Updated: 09/26/2026